Parsippany, NJ—DSM announced a new partnership with Mile High Labs (MHL). According to a press release, the two companies will work together to develop unique hemp-derived cannabinoid solutions.
“There is a strong consumer pull in the CBD space for high-quality, health-benefit driven solutions, but as yet the market is still to arrive at recognized science or quality standards,” said Frederic Boned, Vice President, Human Nutrition & Health at DSM North America, in the press release. “DSM has the core competencies, combined with a deep understanding of consumer and customer needs, to help brands enter the cannabinoid market early and build a leading position. Our science-backed solutions will deliver the purity, reliability and traceability that are currently lacking and enable our customers to truly differentiate themselves. MHL is the ideal partner due to its staunch commitment to sustainability, quality and regulatory compliance, as well as its extensive cannabinoid manufacturing capabilities. Together, we are committed to developing the standards the cannabinoid industry sorely needs. Our complementary areas of expertise will support customers along the entire product development process.”
Jonathan Hilley, CEO at MHL, added: “MHL is excited to team up with such a credible player in human nutrition and health, and one that so closely aligns with our ambitions to uncover the full potential of this space. This partnership is an important milestone in the evolution of MHL and a defining moment for our industry. We look forward to pooling our expertise to deliver cannabinoid innovation that is scalable, sustainable, cost-effective and provides the building blocks for exciting new consumer products.”
DSM will make use of MHL’s 400,000 square-feet of manufacturing facilities to apply its scientific, applications, and formulations expertise to combine CBD and other hemp derivatives with micronutrients. The resulting market-ready and premix solutions will enable speedy product development.
“This is just the beginning for DSM. Our partnership with MHL will be a key enabler for us as we take our first steps in this burgeoning market,” concludes DSM’s Boned. “The potential of CBD and other hemp-derived cannabinoids hasn’t yet been fully realized, so we’re investing in the future of the category. As regulatory frameworks are defined, DSM’s end-to-end capabilities and unrivalled portfolio make us ideally positioned to lead and shape the market. This category is full of promise, and we’re excited to partner with MHL and play an integral role in tapping into the potential and enabling customers to create products with real purpose. Watch this space!”